WO2009010660A3 - Indazoles substitues, leur preparation et leur utilisation en therapeutique - Google Patents

Indazoles substitues, leur preparation et leur utilisation en therapeutique Download PDF

Info

Publication number
WO2009010660A3
WO2009010660A3 PCT/FR2008/000843 FR2008000843W WO2009010660A3 WO 2009010660 A3 WO2009010660 A3 WO 2009010660A3 FR 2008000843 W FR2008000843 W FR 2008000843W WO 2009010660 A3 WO2009010660 A3 WO 2009010660A3
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
group
heterocycloalkyl
alkenyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2008/000843
Other languages
English (en)
Other versions
WO2009010660A2 (fr
Inventor
Michel Aletru
Dominique Damour
Catherine Monseau
Patrick Mougenot
Claudie Namane
Frederico Nardi
Patrick Nemecek
Christophe Philippo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39126183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2009010660(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to EP08826411A priority Critical patent/EP2170865A2/fr
Priority to JP2010512736A priority patent/JP2010530402A/ja
Publication of WO2009010660A2 publication Critical patent/WO2009010660A2/fr
Publication of WO2009010660A3 publication Critical patent/WO2009010660A3/fr
Priority to US12/636,357 priority patent/US20100298377A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention est relative à des composés de formule (I) dans laquelle : E désigne un groupement : (i) de formule -NT-CO-O- ou -NT-CX-NT'- dans laquelle X désigne =O ou =S et T et T', pouvant être identiques ou différents, sont choisis indépendamment parmi H ou un groupe alkyle ou (ii) formant un cycle à 5 ou 6 chaînons qui est rattaché en position 5 ou 6 au noyau indazole par -NT- ou par l'atome d'azote N1; R1 représente un ou plusieurs substituant(s), choisis indépendamment l'un de l'autre lorsqu'il y en a plusieurs, pouvant être : un atome d'halogène, un groupe alkyle, alkényle, alkynyle, halogénoalkyle, halogénoalcoxy, aryle, hétéroaryle, hétérocycloalkyle, cycloalkyle, CN, NRR', OR, NO2, COOR, CONRR', NRCOR'; R2 représente un atome d'hydrogène, un groupe alkyle, alkényle ou alkynyle; R3 représente un ou plusieurs substituant(s), choisis indépendamment l'un de l'autre lorsqu'il y en a plusieurs et pouvant être : un atome d'halogène, un groupe alkyle, alkényle, alkynyle, halogénoalcoxy, aryle, hétéroaryle, cycloalkyle, hétérocycloalkyle, CN, NRR', CF3, OR, NO2, COOR, CONRR', NRCOR'; R4 désigne un atome d'hydrogène ou d'halogène, un groupe alkyle, alkényle, alkynyle, aryle, hétéroaryle, hétérocycloalkyle, -NR-CO-R', COOR, NRR', CHO, CONR(OR'); R et R', pouvant être identiques ou différents, désignent indépendamment l'un de l'autre : un atome d'hydrogène, un groupe alkyle, aryle, hétérocycloalkyle, cycloalkyle ou hétéroaryle; n1 représente un nombre entier allant de 0 à 5 et n3 un nombre entier allant de 0 à 3.
PCT/FR2008/000843 2007-06-21 2008-06-18 Indazoles substitues, leur preparation et leur utilisation en therapeutique Ceased WO2009010660A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP08826411A EP2170865A2 (fr) 2007-06-21 2008-06-18 Indazoles substitues, leur preparation et leur utilisation en therapeutique
JP2010512736A JP2010530402A (ja) 2007-06-21 2008-06-18 置換インダゾール類、それらの調製および治療におけるその使用
US12/636,357 US20100298377A1 (en) 2007-06-21 2009-12-11 Novel substituted indazoles, the preparation thereof and use of same in therapeutics

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0704422 2007-06-21
FR0704422A FR2917735B1 (fr) 2007-06-21 2007-06-21 Nouveaux indazoles substitutes, leur preparation et leur utilisation en therapeutique

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/636,357 Continuation US20100298377A1 (en) 2007-06-21 2009-12-11 Novel substituted indazoles, the preparation thereof and use of same in therapeutics

Publications (2)

Publication Number Publication Date
WO2009010660A2 WO2009010660A2 (fr) 2009-01-22
WO2009010660A3 true WO2009010660A3 (fr) 2009-04-16

Family

ID=39126183

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2008/000843 Ceased WO2009010660A2 (fr) 2007-06-21 2008-06-18 Indazoles substitues, leur preparation et leur utilisation en therapeutique

Country Status (11)

Country Link
US (1) US20100298377A1 (fr)
EP (1) EP2170865A2 (fr)
JP (1) JP2010530402A (fr)
AR (1) AR067051A1 (fr)
CL (1) CL2008001815A1 (fr)
FR (1) FR2917735B1 (fr)
PA (1) PA8785301A1 (fr)
PE (1) PE20090369A1 (fr)
TW (1) TW200909425A (fr)
UY (1) UY31166A1 (fr)
WO (1) WO2009010660A2 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2464232B1 (fr) 2009-08-10 2015-10-07 Samumed, LLC Composés d indazole inhibant la voie de signalisation des wnt et utilisations thérapeutiques de ceux-cithereof
SMT201700581T1 (it) 2009-12-21 2018-01-11 Samumed Llc 1h-pirazolo[3,4-b]piridine e loro usi terapeutici
US8569511B2 (en) * 2011-04-01 2013-10-29 University Of Utah Research Foundation Substituted 3-(1H-benzo[d]imidazol-2-yl)-1H-indazole analogs as inhibitors of the PDK1 kinase
AU2012308570B2 (en) 2011-09-14 2016-11-10 Samumed, Llc Indazole-3-carboxamides and their use as Wnt/b-catenin signaling pathway inhibitors
KR20130073822A (ko) * 2011-12-23 2013-07-03 가부시키가이샤 한도오따이 에네루기 켄큐쇼 이온 액체, 비수 전해질 및 축전 장치
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
ME03573B (fr) 2012-05-04 2020-07-20 Samumed Llc 1h-pyrazolo[3,4-b]pyridines et leurs utilisations thérapeutiques
CN105120862A (zh) 2013-01-08 2015-12-02 萨穆梅德有限公司 Wnt信号途径的3-(苯并咪唑-2-基)-吲唑抑制剂及其治疗应用
EP2970177A1 (fr) 2013-03-15 2016-01-20 Pfizer Inc. Composés indoliques activant l'ampk
WO2016040180A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 3-1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
WO2016040188A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 3-3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
WO2016040181A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 3-1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
WO2016040193A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine et ses utilisations thérapeutiques
WO2016040184A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 3-3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
WO2016040185A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 2-1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine et ses utilisations thérapeutiques
WO2016040182A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine et ses utilisations thérapeutiques
WO2016040190A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine et ses utilisations thérapeutiques
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
US10195185B2 (en) 2015-08-03 2019-02-05 Samumed, Llc 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10519169B2 (en) 2015-08-03 2019-12-31 Samumed, Llc 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10383861B2 (en) 2015-08-03 2019-08-20 Sammumed, LLC 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017024015A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
US10285983B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof
WO2017023989A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
US10226448B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
WO2017023988A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
WO2017023980A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines et leurs utilisations thérapeutiques
US10463651B2 (en) 2015-08-03 2019-11-05 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof
WO2017024004A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
WO2017024026A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-indol-2-yl)-1h-pyrazolo[3,4-c]pyridines et leurs utilisations thérapeutiques
US10604512B2 (en) 2015-08-03 2020-03-31 Samumed, Llc 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof
WO2017024003A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
US10350199B2 (en) 2015-08-03 2019-07-16 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
US10206908B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017023993A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
CN108473491A (zh) 2015-11-06 2018-08-31 萨穆梅德有限公司 2-(1h-吲唑-3-基)-3h-咪唑并[4,5-c]吡啶以及其抗炎用途
DK3464285T3 (da) 2016-06-01 2022-12-19 Biosplice Therapeutics Inc Fremgangsmåde til fremstilling af n-(5-(3-(7-(3-fluorphenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamid
EP3528808B1 (fr) 2016-10-21 2021-10-06 BioSplice Therapeutics, Inc. Procédés d'utilisation d'indazole-3-carboxamides et leur utilisation en tant qu'inhibiteurs de la voie de signalisation wnt/ -caténine
MA46696A (fr) 2016-11-07 2019-09-11 Samumed Llc Formulations injectables à dose unique prêtes à l'emploi
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) * 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
GB201903827D0 (en) * 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002010137A2 (fr) * 2000-07-31 2002-02-07 Signal Pharmaceuticals, Inc. Derives d'indazole utilises comme inhibiteurs de jnk et compositions et methodes associees a ceux-ci
FR2836914A1 (fr) * 2002-03-11 2003-09-12 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
WO2005037792A1 (fr) * 2003-10-17 2005-04-28 Sanofi-Aventis Derives de n-``phenyl(piperidin-2-yl)methyl !benzamide, leur preparation et leur application en therapeutique
WO2006135383A2 (fr) * 2004-08-04 2006-12-21 Myriad Genetics, Inc. Indazoles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2690440B1 (fr) * 1992-04-27 1995-05-19 Rhone Poulenc Agrochimie Arylpyrazoles fongicides.
FR2823209B1 (fr) * 2001-04-04 2003-12-12 Fournier Lab Sa Nouvelles thiohydantoines et leur utilisation en therapeutique
FR2838739B1 (fr) * 2002-04-19 2004-05-28 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl)benzamide, leur preparation et leur application en therapeutique
DE102005059479A1 (de) 2005-12-13 2007-06-14 Merck Patent Gmbh Hydroxychinolinderivate
WO2009059961A2 (fr) 2007-11-06 2009-05-14 N.V. Organon Procédé de diminution du taux d'hormone chez les êtres humains

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002010137A2 (fr) * 2000-07-31 2002-02-07 Signal Pharmaceuticals, Inc. Derives d'indazole utilises comme inhibiteurs de jnk et compositions et methodes associees a ceux-ci
FR2836914A1 (fr) * 2002-03-11 2003-09-12 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
WO2003078402A1 (fr) * 2002-03-11 2003-09-25 Aventis Pharma S.A. Indazoles substitues avec une activite anticancereuse
WO2005037792A1 (fr) * 2003-10-17 2005-04-28 Sanofi-Aventis Derives de n-``phenyl(piperidin-2-yl)methyl !benzamide, leur preparation et leur application en therapeutique
WO2006135383A2 (fr) * 2004-08-04 2006-12-21 Myriad Genetics, Inc. Indazoles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DUMAS J: "PROTEIN KINASE INHIBITORS FROM THE UREA CLASS", CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, CURRENT DRUGS, LONDON, GB, vol. 5, no. 5, 2002, pages 718 - 727, XP009011493, ISSN: 1367-6733 *

Also Published As

Publication number Publication date
CL2008001815A1 (es) 2009-09-11
UY31166A1 (es) 2009-01-30
TW200909425A (en) 2009-03-01
EP2170865A2 (fr) 2010-04-07
US20100298377A1 (en) 2010-11-25
PE20090369A1 (es) 2009-04-30
FR2917735B1 (fr) 2009-09-04
JP2010530402A (ja) 2010-09-09
AR067051A1 (es) 2009-09-30
WO2009010660A2 (fr) 2009-01-22
PA8785301A1 (es) 2009-01-23
FR2917735A1 (fr) 2008-12-26

Similar Documents

Publication Publication Date Title
EA200970656A1 (ru) Вич-ингибирующие 5,6-замещенные пиримидины
ATE556058T1 (de) 1-(2h)-isochinolonderivat
MX2009008509A (es) Compuesto de anillo puenteado-aza.
JP2008530099A5 (fr)
WO2009156861A8 (fr) Dérivés de pyrimidone substitués
AR067051A1 (es) Indazoles sustituidos, su preparacion y su utilizacion terapeutica
NO20074641L (no) 1-Acetic Acid-Indole Derivatives with PGD2 Antagonist Activity
JP2010504286A5 (fr)
PH12014501486A1 (en) Novel nicotinamide derivative or salt thereof
NO20092770L (no) Nye aminopyrimidinderivater som PLK1-inhibitorer
NZ603896A (en) 3-amino-5,6-dihydro-1h-pyrazin-2-one derivatives useful for the treatement of alzheimer's disease and other forms of dementia
AR082519A1 (es) Fenilamidinas que tienen alta actividad fungicida, y su utilizacion
NO20074311L (no) Kinazolinderivat med tyrosinkinase-inhiberendeaktivitet
WO2008107502A8 (fr) Composition destinée à traiter des maladies infectieuses
WO2009095792A3 (fr) Dérivés d'hétéroarylamide diazépinopyrimidone substitués
PH12014500775A1 (en) Ethynyl derivatives as mglur5 allosteric modulators
HRP20160001T1 (hr) Postupak za pripravu fenil supstituiranih n-metoksi-[1-metil-2-feniletil]amida 3-difluorometil-1-metil-1h-pirazol-4-karboksilne kiseline
NO20064297L (no) Aminoalkoholforbindelse
DK2868660T3 (da) Anti-tumoreffekt-potentiator omfattende en imidazooxazin-forbindelse
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
TNSN07439A1 (en) Derivatives of,4,5 - diarylpyrrole, preparation method thereof and use of same in therapeutics
WO2008003858A3 (fr) Utilisation de dérivés d'imidazo[1, 2-a]pyridine-2-carboxamides en thérapeutique
ATE396183T1 (de) Chromanderivate und ihre verwendung als liganden des 5-ht-rezeptors
DE602007008736D1 (de) 1h-furoä3,2-cü pyrazolverbindungen, die sich als kinaseinhibitoren eignen
AR056418A1 (es) Derivados de bencimidazol como 5-ht6, 5-ht2a, metodo para la obtencion del compuesto y el uso para la fabricacion de un mediicamento

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08826411

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008826411

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010512736

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE